Skip to main content
. 2020 Sep 15;202(6):866–877. doi: 10.1164/rccm.201912-2489OC

Figure 7.

Figure 7.

Pharmacokinetic profiles of rifapentine following (A) a regimen of daily isoniazid-rifapentine for 1 month and (B) a regimen of once-weekly rifapentine-isoniazid for 3 months. Concentration–time profiles over 24 hours are shown for the typical adult by HIV status on (A) Day 21 of therapy, to reflect steady-state concentrations, and (B) after the first dose, as no accumulation occurs with weekly dosing.